## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.1% below STRENGTH zone (3.0-6.0%); PEG 1.27 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($463.02)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 1)

**1. 2 Soaring Healthcare Stocks to Buy and Hold for a Decade**
- Source: Finviz | 20251204T120942 | Bullish | Relevance: 100%
- This article highlights HCA Healthcare (NYSE: HCA) and CVS Health (NYSE: CVS) as two healthcare stocks with significant upside potential over the next decade. Both companies have seen impressive stock performance in the past year, and the author argues they are well-positioned for future growth due to strategic initiatives, an aging population, and expanding market reach.

**2. HCA’s Cash Machine Looks Cheap After A Healthy Run**
- Source: Finimize | 20251203T145120 | Somewhat-Bullish | Relevance: 100%
- HCA Healthcare, the largest for-profit hospital operator in the U.S., has shown strong recent performance with a 56.6% total return over 12 months and raised full-year guidance for 2025. Despite policy risks and labor cost inflation, its robust cash generation, strong margins, and perceived valuation discount make it an appealing opportunity for long-term investors, though the stock carries risks associated with leverage and regulatory uncertainty.

**3. HCA Healthcare Stock Near Record Highs: December 2025 Earnings, Forecasts and Policy Risks Explained**
- Source: ts2.tech | 20251203T003617 | Bullish | Relevance: 100%
- HCA Healthcare (NYSE: HCA) is approaching record highs in December 2025, driven by strong earnings growth, upgraded guidance, and a strategic focus on outpatient expansion. The article details HCA's financial performance, analyst sentiment, and potential policy risks like the expiration of ACA premium tax credits. While momentum is strong, some analysts suggest the stock might be overextended in the short term.

**4. American Century Companies Inc. Boosts Stake in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251203T190854 | Bullish | Relevance: 100%
- American Century Companies Inc. significantly increased its stake in HCA Healthcare by 107.7% in Q2, acquiring an additional 26,188 shares, bringing their total to 50,509 shares valued at approximately $19.35 million. HCA Healthcare exceeded Q3 expectations with $6.96 EPS and $19.16 billion in revenue, and has set optimistic FY2025 guidance at 27.00–28.00 EPS. The company also declared a quarterly dividend of $0.72 and maintains a "Moderate Buy" consensus analyst rating.

**5. HCA Healthcare Inc. stock underperforms Wednesday when compared to competitors**
- Source: MarketWatch | 20251203T163800 | Bearish | Relevance: 100%
- Shares of HCA Healthcare Inc. (HCA) fell 2.71% on Wednesday to close at $486.77, underperforming the broader market. This marks the stock's fifth consecutive day of losses despite an otherwise positive trading session for the S&P 500 and Dow Jones Industrial Average.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.8% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $15M sold (4 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.27 suggests fair value with growth premium. Forward P/E 16.4x stretched relative to 7% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $111.6B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.27 |
| Forward P/E | 16.4 |
| Current P/E | 17.6 |
| YoY Growth | 7.3% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 0.7% to -4.1% (-4.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.1pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.81), momentum weakening. RSI neutral at 55. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.10% (CS: 10) | Weak |
| RSI_14 | 55.3 | Neutral |
| MACD Histogram | -1.81 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.260x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $487.66
- **Stop Loss:** $463.02 (5.1% risk)
- **Target:** $512.30 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $9,753.20
- **Portfolio %:** 9.75%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*